Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ethypharm Gains EU Approval for Morphine Immediate Release Tablets
Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 12, 2021
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
Details : U.S. Food and Drug Administration approved the Company’s Abbreviated New Drug Application for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System.
Product Name : Morphine Sulfate-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable